Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Liminatus Pharma Inc. (LIMN) had Normalized Income after Taxes of $0.00M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.00M |
|
-- |
|
-- |
|
$-0.00M |
|
$0.00M |
|
-- |
|
$0.00M |
|
$0.00M |
|
$0.00M |
|
$0.00M |
|
$0.00M |
|
|
Normalized Income after Taxes |
$0.00M |
$0.00M |
|
$0.00M |
|
0.00M |
|
0.00M |
|
$-2.55 |
|
$-2.55 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
$0.00M |
|
-- |
|
-- |
|
$0.00M |
|
$-0.00M |
|
$-0.00M |
|
$-0.00M |
|
0.00M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|